
Citation: Xin Nian, Yasuhiro Nagai, Cameron Jeffers, Kara N. Maxwell, Hongtao Zhang. Dietary influence on estrogens and cytokines in breast cancer[J]. AIMS Molecular Science, 2017, 4(3): 252-270. doi: 10.3934/molsci.2017.3.252
[1] | Avner Friedman, Chuan Xue . A mathematical model for chronic wounds. Mathematical Biosciences and Engineering, 2011, 8(2): 253-261. doi: 10.3934/mbe.2011.8.253 |
[2] | Pedro José Gutiérrez-Diez, Jose Russo . Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia. Mathematical Biosciences and Engineering, 2020, 17(5): 4773-4800. doi: 10.3934/mbe.2020261 |
[3] | Laurenz Göllmann, Helmut Maurer . Optimal control problems with time delays: Two case studies in biomedicine. Mathematical Biosciences and Engineering, 2018, 15(5): 1137-1154. doi: 10.3934/mbe.2018051 |
[4] | Jerzy Klamka, Helmut Maurer, Andrzej Swierniak . Local controllability and optimal control for\newline a model of combined anticancer therapy with control delays. Mathematical Biosciences and Engineering, 2017, 14(1): 195-216. doi: 10.3934/mbe.2017013 |
[5] | Glenn Webb . The force of cell-cell adhesion in determining the outcome in a nonlocal advection diffusion model of wound healing. Mathematical Biosciences and Engineering, 2022, 19(9): 8689-8704. doi: 10.3934/mbe.2022403 |
[6] | Elamin H. Elbasha . Model for hepatitis C virus transmissions. Mathematical Biosciences and Engineering, 2013, 10(4): 1045-1065. doi: 10.3934/mbe.2013.10.1045 |
[7] | B. M. Adams, H. T. Banks, Hee-Dae Kwon, Hien T. Tran . Dynamic Multidrug Therapies for HIV: Optimal and STI Control Approaches. Mathematical Biosciences and Engineering, 2004, 1(2): 223-241. doi: 10.3934/mbe.2004.1.223 |
[8] | Heping Ma, Hui Jian, Yu Shi . A sufficient maximum principle for backward stochastic systems with mixed delays. Mathematical Biosciences and Engineering, 2023, 20(12): 21211-21228. doi: 10.3934/mbe.2023938 |
[9] | Minseok Kim, Yeongjong Kim, Yeoneung Kim . Physics-informed neural networks for optimal vaccination plan in SIR epidemic models. Mathematical Biosciences and Engineering, 2025, 22(7): 1598-1633. doi: 10.3934/mbe.2025059 |
[10] | Taeyong Lee, Adrianne L. Jenner, Peter S. Kim, Jeehyun Lee . Application of control theory in a delayed-infection and immune-evading oncolytic virotherapy. Mathematical Biosciences and Engineering, 2020, 17(3): 2361-2383. doi: 10.3934/mbe.2020126 |
Chronic wounds, which fail to heal through the normally orderly process of stages and remain in a chronic inflammatory state, are a major burden for health care systems and a significant socioeconomic problem worldwide [1,2]. For example, 2.4–4.5 million people are believed to suffer from the chronic lower extremity ulcers (a typical chronic wound disease) per year in the United States [3]. These ulcers last on average 12 months and recur up to 60% to 70% of patients. In a Dutch nursing-home population, a recent study shows a 4.2% prevalence rate of chronic wounds [4]. Chronic wounds lead to loss of basic functions of human body and decrease quality of life tremendously. Along with other diseases such as diabetes, 24% of these wounds will ultimately result in amputation of the lower limb. Thus, effective treatment for chronic wounds is urgently needed.
The dynamic evolution process of the chronic wound mainly consists the oxygen, neutrophils, invasive bacteria, and chemoattractant (a chemical that attracts neutrophils to the bacteria). There are many useful mathematical models that address these four physical and chemical phenomenon. McDougall et al. model the dermal wound healing by a weighted average of cells' previous motion direction [5]. Cumming et al. use a cell-based discrete approach to describe the delicate interaction between elements that vary widely in nature and size scales [6]. Gaffney et al. use standard form of the conservation equation for the tip concentration and the endothelial cell density [7]. Thackham et al. consider advection-dominated wound healing models with a source term and obtain an analytic solution under some simplification [8]. Vermolen has developed a system of two dimensional nonlinear reaction-diffusion equations, in which oxygen, growth factors, epidermal cells are considered [9]. Essentially, the dynamic evolution process of the chronic wound is spatiotemporal evolution, which is generally modeled by coupled partial differential equations (PDEs). For example, continuum reaction-diffusion models, one of typical PDEs, are the most commonly theoretical approach to study the angiogenesis process [10].
Wound healing is a highly regulated and undeniably complex process, which can be divided into four interconnected and overlapping stages: haemostasis, inflammation, proliferation and remodelling [11,12]. Among these processes, hyperbaric oxygen therapy is a critical means for healing the wound and has been shown to improve the healing of chronic wounds in clinical trials [13]. Hyperbaric oxygen therapy is breathing 100% oxygen under increased atmospheric pressure. The primary mechanism behind the use of this therapy for wound healing is to correct the amount of oxygen delivered to the wound site. The positive effects stem from increased tissue oxygen tension and pressure within the wound site, such as increased collagen synthesis, modulation of the immune system response, inhibition of bacterial propagation, prevention of leukocyte activation and so on [14]. Kalliainen et al. conclude that topical oxygen has no bad effects on chronic wounds and show the beneficial indications in promoting wound healing [15]. Gajendrareddy et al. demonstrate that systemic oxygen therapy ameliorates stress-impaired dermal wound healing [16]. Eisenbud gives the correction of wound hypoxia and clarifies that oxygen is beneficial to many aspects of healing but it does not necessarily follow that the more is better [17]. These work described above greatly promotes the hyperbaric oxygen therapy and provides guidance for the medical staff. However, these results are from a large number of repeated experiments and feel weak for individual difference treatment. Moreover, Gill et al. discuss the application, mechanisms and outcomes of the hyperbaric oxygen therapy but also mention that the therapy is expensive [18]. Thus, this paper considers the hyperbaric oxygen therapy for a chronic wound from the perspective of control synthesis and economic cost.
To our best knowledge, there are few literature studies in the control of the hyperbaric oxygen therapy for a chronic wound. The time and amount of oxygenation applied during the hyperbaric oxygen therapy provide the regulatory mechanism for the advanced control strategy study to improve wound healing [19,20]. Recently, Guffey demonstrates the existence of the state solutions for a bacterial infection model with modified boundary conditions [21] and establishes some theoretical foundations of optimal control in a chronic wound. However, the convergence of the state system forward and the adjoint system backward is not solved and the implementation of optimal control is blocked. In this paper, we complement the optimal switching time control of the hyperbaric oxygen therapy for a chronic wound based on the sensitivity analysis and have a great prospect in the application and guidance of the hyperbaric oxygen therapy.
The paper is organized as follows. In Section 2, the dimensionless oxygen concentration, dimensionless neutrophil concentration, dimensionless bacterial concentration and dimensionless chemoattractant concentration with corresponding boundary conditions and initial conditions in a chronic wound are modeled. Then, the optimal control problem for inhibiting the growth of bacterial concentration through the hyperbaric oxygen therapy is proposed. In Section 3, The method of lines, which only discretizes the space while keeps the time continuous, is used to reduce the PDE optimization problem into an ODE optimization problem. In Section 4, the control design problem of the hyperbaric oxygen therapy is the parameter selection problem of the optimal time switching points essentially. However, the switching time problem is difficult to solve. Thus, the time-scaling transformation approach which turns the original problem into a new problem with fixed switching time is applied and the gradient of the cost functional corresponding to the time intervals is derived based on the sensitivity analysis. In Section 5, computational numerical analysis is carried out to show the effectiveness of the optimal switching time control for bacterial concentration suppression under different discretization numbers of the time intervals. Finally, Section 6 concludes the paper with comments and suggestions for future research.
We consider the situation, where the chronic wound is considered to be one-dimensional with the spatial distance x=0 located at the center of the radial wound site and x=1 located at the edge of the chronic wound nearest healthy dermis. This paper mainly uses oxygen, neutrophils, bacteria and chemoattractants to describe the dynamic evolution process of a chronic wound. Moreover, the relationship of these variables' interaction is shown in Figure 1.
The movement process of the dimensionless oxygen concentration O(x,t) in a chronic wound is governed by the following PDE model [22,23]
∂O(x,t)∂t=∂2O(x,t)∂x2+η+κu(t)−λNON(x,t)O(x,t)−λBOB(x,t)O(x,t)−λOO(x,t),t∈[0,T],x∈[0,1], | (2.1) |
where t is the time variable; η is a constant input of external oxygen; κ is the oxygen coefficient of the hyperbaric oxygen therapy; λNO is per unit neutrophil; λBO is per unit bacteria; N(x,t) is the dimensionless neutrophil concentration; B(x,t) is the dimensionless bacterial concentration; λO is the natural decay rate of oxygen. Oxygen lost in any other way, unrelated to the neutrophils and bacteria, occurs at a constant rate of λO. For example, other leukocytes need to consume oxygen. Oxygen naturally decay is also described in [24]. Moreover, during the hyperbaric oxygen therapy, we can only choose the oxygen tank on or off. Thus, u(t), a time-dependent oxygen therapy, is given as
u(t)={1,if oxygen is imposed,0,otherwise. | (2.2) |
Since the oxygen concentration satisfies the natural boundary condition at the center of the chronic wound and is enough at the edge of the chronic wound nearest healthy dermis, the boundary conditions for (2.1) are:
∂O(0,t)∂x=0,O(1,t)=1,t∈[0,T]. | (2.3) |
We assume the initial state of the oxygen concentration is enough and then obtain the following initial condition for (2.1)
O(x,0)=1,x∈[0,1]. | (2.4) |
The movement process of the dimensionless neutrophil concentration in a chronic wound is governed by [25,26]
∂N(x,t)∂t=DN∂2N(x,t)∂x2−κN∂(∂N(x,t)∂C(x,t)∂x)∂x+αBNB(x,t)N(x,t)GN(O(x,t))(1−N(x,t))−λNN(x,t)(1+HN(O(x,t)))1+eB(x,t),t∈[0,T],x∈[0,1], | (2.5) |
where DN is the diffusion coefficient of neutrophils; κN is the attraction coefficient of neutrophils via chemoattractant gradient released by the bacteria; C(x,t) is the dimensionless chemoattractant concentration; αBN is the proliferation coefficient of neutrophils corresponding to the bacteria and oxygen; λN is the decay coefficient of neutrophils dependent on the presence of bacteria and oxygen, e is the relative coefficient of neutrophils corresponding to the bacteria. As bacteria proliferate in the wound, neutrophils are recruited into the chronic wound site to destroy the bacteria. This direct correlation between the amount of bacteria in the wound and the neutrophil concentration also affects the reduction of neutrophils from the chronic wound. The fraction (the last item on the right side of (2.5)), which is also mentioned in [26], describes this process. Moreover, two bounded smooth functions GN(O(x,t)) and HN(O(x,t)) are defined as
GN(O(x,t))={2O3(x,t)−3O2(x,t)+2, 0≤O(x,t)<1,1,O(x,t)>1, | (2.6) |
and
HN(O(x,t))={2, 0≤O(x,t)<0.15,4000O3(x,t)−2400O2(x,t)+450O(x,t)−25, 0.15≤O(x,t)<0.25,0, 0.25≤O(x,t)<2.95,−4000O3(x,t)+36000O2(x,t)−107970O(x,t)−107911, 2.95≤O(x,t)<3.05,2,O(x,t)>3.05. | (2.7) |
In according with (2.3), the boundary conditions for (2.5) are
∂N(0,t)∂x=0,N(1,t)=1,t∈[0,T]. | (2.8) |
The neutrophils are assumed to be originally concentrated heavily near the edge of the chronic wound, the initial condition for (2.5) is
N(x,0)=x2e−(1−xϵ)2,x∈[0,1], | (2.9) |
where ϵ is the distribution coefficient.
The movement process of the dimensionless bacterial concentration in a chronic wound is governed by the following PDE model [26]
∂B(x,t)∂t=DB∂2B(x,t)∂x2+αBB(x,t)(1−B(x,t))−B(x,t)O(x,t)KO+O(x,t)θ+KNRN(x,t)λRBB(x,t)+1−λBB(x,t),t∈[0,T],x∈[0,1], | (2.10) |
where DB is the diffusion coefficient of bacteria; αB is the proliferation coefficient of bacteria; KO is the influence coefficient of oxygen; θ is the influence coefficient of other leukocytes; KNR is the influence coefficient of neutrophils; λRB is the attenuation coefficient of neutrophils' influence; λB is the natural death rate of bacteria. Bacteria are removed by neutrophils. An increase in the neutrophil concentration within the wound site will lead to the destruction of bacteria. Thus, KNR denotes the influence coefficient of neutrophils for bacterial destruction while λRB denotes the attenuation coefficient of neutrophils' influence caused by bacteria. Since the bacterial concentration satisfies the natural boundary condition (a zero flux condition) at x=0 and x=1, the boundary conditions for (2.10) are
∂B(0,t)∂x=0,∂B(1,t)∂x=0,t∈[0,T]. | (2.11) |
Meanwhile, the bacteria are assumed to be initially concentrated densely in the center of the chronic wound within [0,ϵ] and nonexistent elsewhere. It is corresponding to the neutrophils, which are assumed to be initially concentrated heavily near the edge of the chronic wound. Then, neutrophils are chemically attracted by the chemoattractant to destroy bacteria. Moreover, the assumption that bacteria are initially concentrated in the center of the chronic wound is mentioned in [26]. In practice, the process of bacteria slowly moving from a central area of a wound to the outer edge is reasonable. Thus, the initial condition for (2.10) is
B(x,0)=(1−x)2e−(xϵ)2,x∈[0,1]. | (2.12) |
where ϵ is the distribution coefficient like in (2.9).
The movement process of the dimensionless chemoattractant concentration in a chronic wound is governed by [27]
∂C(x,t)∂t=DC∂2C(x,t)∂x2+αCB(x,t)−λCC(x,t),t∈[0,T],x∈[0,1], | (2.13) |
where DC is the diffusion coefficient of chemoattractant; αC is the proliferation coefficient of chemoattractant produced by the bacteria; λC is natural death rate of chemoattractant. In accordance with (2.11), the boundary conditions for (2.13) are
∂C(0,t)∂x=0,∂C(1,t)∂x=0,t∈[0,T]. | (2.14) |
In accordance with (2.12), the initial condition for (2.13) is
C(x,0)=(1−x)2e−(xϵ)2,x∈[0,1]. | (2.15) |
where ϵ is the distribution coefficient like in (2.9).
Since bacterial concentration causes a serious threat to health cure, the hyperbaric oxygen therapy u(t) must be manipulated carefully to inhibit the growth of bacterial concentration and even eliminate bacteria at fixed treatment time t=T. Gill et al. mention that hyperbaric oxygen therapy is expensive. The cost of this therapy depends on the amount of time it takes to use oxygen. We hope to achieve better therapeutic results at a lower economic cost, which has important socioeconomic significance. The cost functional is designed to minimize the bacterial infection as well as the amount of time spent in the hyperbaric oxygen therapy. To this end, we consider the following cost functional
J(u(t))=∫10B(x,T)dx+ω∫T0u2(t)dt, | (2.16) |
where ω is the weight coefficient, which depends on the treatment cost. The first term of cost functional (2.16) denotes the bacterial concentration at fixed treatment time t=T and the second term denotes the economic cost by hyperbaric oxygen therapy. This paper considers the inhibition of bacterial propagation and even completes the elimination of bacteria to achieve a smooth healing of a chronic wound through the hyperbaric oxygen therapy. Thus, bacterial concentration is the most direct variable and an objective evaluation criterion for therapeutic effects. Other variables, including oxygen, neutrophils and chemoattractants, are coupled with bacteria through PDEs. It is difficult to obtain the direct quantitative relationship between bacteria and indirect variables and then hard to include these indirect variables in the cost functional to obtain an objective evaluation criterion. For example, chemoattractant attracts neutrophils to destroy bacteria while chemoattractant is produced by bacteria. Thus, the chemoattractant concentration is difficult to be quantified in the cost functional. Moreover, the proposed objective function is also used in [21].
Thus, we obtain the following PDE optimization problem: given the dimensionless oxygen concentration model (2.1), dimensionless neutrophil concentration model (2.5), dimensionless bacterial concentration model (2.10) and dimensionless chemoattractant concentration model (2.13) with corresponding boundary conditions and initial conditions, choose the control u(t), in accordance with (2.2), to minimize the cost functional (2.16). We refer to this problem as Problem P0.
Problem P0 is a PDE optimization problem. In order to simplify the optimal control design, we apply the method of lines, which only discretizes the space while keeps the time continuous, to reduce the PDEs (2.1), (2.5), (2.10) and (2.13) into ODEs [28]. First, we decompose the whole space [0,1] into equally-spaced intervals xi−xi−1=1/M, i=1,...,M, where M is an integer of spatial discretization, x0=0,xM=1 and define
O(xi,t)=Oi(t),N(xi,t)=Ni(t),B(xi,t)=Bi(t),C(xi,t)=Ci(t),i=0,...,M. | (3.1) |
Then, based on the (3.1), we obtain the following finite difference approximations by center difference
∂2O(xi,t)∂x2=M2[Oi+1(t)−2Oi(t)+Oi−1(t)],∂2N(xi,t)∂x2=M2[Ni+1(t)−2Ni(t)+Ni−1(t)],∂2B(xi,t)∂x2=M2[Bi+1(t)−2Bi(t)+Bi−1(t)],∂2C(xi,t)∂x2=M2[Ci+1(t)−2Ci(t)+Ci−1(t)],i=1,...,M−1, | (3.2) |
and
∂(∂N(x,t)∂C(x,t)∂x)∂x=M24[Ni+1(t)−Ni−1(t)][Ci+1(t)−Ci−1(t)]+M2Ni(t)[Ci+1(t)−2Ci(t)+Ci−1(t)],i=1,...,M−1. | (3.3) |
Thus, based on the (3.2) and (3.3), the dimensionless oxygen concentration model (2.1), dimensionless neutrophil concentration model (2.5), dimensionless bacterial concentration model (2.10) and dimensionless chemoattractant concentration model (2.13) become
dOi(t)dt=M2[Oi+1(t)−2Oi(t)+Oi−1(t)]+η+κu(t)−λNONi(t)Oi(t)−λBOBi(t)Oi(t)−λOOi(t), | (3.4a) |
dNi(t)dt=DNM2[Ni+1(t)−2Ni(t)+Ni−1(t)]−κN{M24[Ni+1(t)−Ni−1(t)][Ci+1(t)−Ci−1(t)]+M2Ni(t)[Ci+1(t)−2Ci(t)+Ci−1(t)]}+αBNBi(t)Ni(t)GN(Oi(t))(1−Ni(t))−λNNi(t)(1+HN(Oi(t)))1+eBi(t), | (3.4b) |
dBi(t)dt=DBM2[Bi+1(t)−2Bi(t)+Bi−1(t)]+αBBi(t)(1−Bi(t))−Bi(t)Oi(t)KO+Oi(t)θ+KNRNi(t)λRBBi(t)+1−λBBi(t), | (3.4c) |
dCi(t)dt=DCM2[Ci+1(t)−2Ci(t)+Ci−1(t)]+αCBi(t)−λCCi(t),i=1,...,M−1. | (3.4d) |
Under the spatial discretization (3.1), the boundary conditions (2.3) and (2.8) become
O0(t)=O2(t),OM+1(t)=1,N0(t)=N2(t),NM+1(t)=1. | (3.5) |
The boundary conditions (2.11) and (2.14) become
B0(t)=B2(t),BM+1(t)=BM−1(t),C0(t)=C2(t),CM+1(t)=CM−1(t). | (3.6) |
The initial conditions (2.4) and (2.9) become
Oi(0)=1,Ni(0)=x2ie−(1−xiϵ)2,i=0,...,M. | (3.7) |
The initial conditions (2.12) and (2.15) become
Bi(0)=(1−xi)2e−(xiϵ)2,Ci(0)=(1−xi)2e−(xiϵ)2,i=0,...,M. | (3.8) |
Moreover, the cost functional (2.16) becomes
J(u(t))=M−1∑i=0Bi(T)M+ω∫T0u2(t)dt. | (3.9) |
Now, we state our approximate problem as follows: given the ODEs (3.4) with the initial conditions (3.7) and (3.8), choose the control u(t), in accordance with (2.2), to minimize the cost functional (3.9). We refer to this problem as Problem P1.
Problem P1 is an ODE optimization problem, where the control u(t) is limited to 0 or 1. In the hyperbaric oxygen therapy, we should choose the optimal time intervals applied by the oxygen. Note that the time of oxygen inhalation should not be too long, no more than three times a day, no more than 120 minutes (2 hours) each time, otherwise, it is easy to cause oxygen toxicity for a human [29]. First, the whole time horizon [0,T] is divided into γ time intervals [30]
0=t0<t1<⋯<tγ−1<tγ=T. | (4.1) |
where tk,k=1,…,γ−1, are time switching points. However, unequal time intervals [tk−1,tk], k=1,...,γ make the ODE optimization problem difficult to deal with, where the optimized decision variables are the time intervals. Thus, we apply the time-scaling transformation approach to transform the ODE optimization problem with changed switching time into a new optimization problem with fixed switching time [31,32]. The relationship between t (changed switching time) and s (fixed switching time) shown in Figure 2 can be also defined as
dt(s)ds=ζk,s∈[k−1,k),k=1,...,γ, | (4.2) |
where t(0)=0 and t(γ)=T; ζk, k=1,...,γ, are time interval variables, which should be optimized. Let ζ=[ζ1,ζ2,...,ζγ]⊤, where ζk=tk−tk−1,k=1,...,γ and
0≤ζk≤T,γ∑k=1ζk=T, | (4.3) |
and when u(t)=1, 0≤ζk≤Th, where Th denotes 2 hours.
Integrating (4.2) over [0,s], we can obtain the time-scaling function as
t(s)={⌊s⌋∑k=1ζk+ζ⌊s⌋+1(s−⌊s⌋),if s∈[0,γ),T,s=γ, | (4.4) |
where ⌊s⌋ donates an integer which is not larger than s. Accordingly, we should change the Problem P1 with time variable "t" into a new optimization problem with auxiliary variable "s". Let denote
˜Oi(s)=Oi(t(s)),˜Ni(s)=Ni(t(s)),˜Bi(s)=Bi(t(s)),˜Ci(s)=Ci(t(s)),i=0,...,M. | (4.5) |
Combined with the chain rule, the reduced dimensionless oxygen concentration model (3.4) becomes
d˜Oi(s)ds=dOi(t(s))dtdt(s)ds=ζkdOi(t(s))dt,s∈(k−1,k),k=1,…,γ,i=1,...,M−1. | (4.6) |
Based on the (4.6), (3.4) becomes
d˜Oi(s)ds=ζk{M2[˜Oi+1(s)−2˜Oi(s)+˜Oi−1(s)]+η+κu(s)−λNO˜Ni(s)˜Oi(s)−λBO˜Bi(s)˜Oi(s)−λO˜Oi(s)}, | (4.7a) |
d˜Ni(s)ds=ζk{DNM2[˜Ni+1(s)−2˜Ni(s)+˜Ni−1(s)]−κN{M24[˜Ni+1(s)−˜Ni−1(s)][˜Ci+1(s)−˜Ci−1(s)]+˜Ni(s)M2[˜Ci+1(s)−2˜Ci(s)+˜Ci−1(s)]}+αBN˜Bi(s)˜Ni(s)GN(˜Oi(s))(1−˜Ni(s))−λN˜Ni(s)(1+HN(˜Oi(s)))1+e˜Bi(s)}, | (4.7b) |
d˜Bi(s)ds=ζk{DBM2[˜Bi+1(s)−2˜Bi(s)+˜Bi−1(s)]+αB˜Bi(s)(1−˜Bi(s))−˜Bi(s)˜Oi(s)KO+˜Oi(s)θ+˜KNR˜Ni(s)λRB˜Bi(s)+1−λB˜Bi(s)}, | (4.7c) |
d˜Ci(s)ds=ζk{DCM2[˜Ci+1(s)−2˜Ci(s)+˜Ci−1(s)]+αC˜Bi(s)−λC˜Ci(s)},i=1,...,M−1, | (4.7d) |
where s∈(k−1,k),k=1,…,γ. The initial conditions (3.7) and (3.8) become
˜Oi(0)=Oi(0),˜Ni(0)=Ni(0),˜Bi(0)=Bi(0),˜Bi(0)=Bi(0). | (4.8) |
After the time-scaling transformation approach (4.2), the cost functional (3.9) becomes
J(ζ)=M−1∑i=0˜Bi(γ)M+ωγ∑k=1∫kk−1ζku2(s)ds. | (4.9) |
Finally, the optimal parameter selection problem is stated as: given the ODEs (4.7) with the initial conditions (4.8), choose the optimal switching time points tk,k=1,…,γ−1 combined with the control u(t) to minimize the cost functional (4.9). We refer to this problem as Problem Pγ.
Problem Pγ is a nonlinear programming problem. Thus, we should compute the gradient of the cost functional (4.9) corresponding to the time interval variables ζk,k=1,...,γ. However, computing its gradient is a non-trivial task since (4.9) is an implicit, rather than an explicit function.
For each μ=1,2,…,γ and i=1,...,M−1, we apply the integration and obtain
˜Oi(s)=˜Oi(μ−1)+∫sμ−1ζμ{M2[˜Oi+1(β)−2˜Oi(β)+˜Oi−1(β)]+η+κu(β)−λNO˜Ni(β)˜Oi(β)−λBO˜Bi(β)˜Oi(β)−λO˜Oi(β)}dβ,s∈[μ−1,μ). | (4.10) |
If k≤μ, we differentiate (4.10) corresponding to ζk and obtain
∂˜Oi(s)∂ζk=∂˜Oi(μ−1)∂ζk+∫sμ−1ζμ{M2[∂˜Oi+1(β)∂ζk−2∂˜Oi(β)∂ζk+∂˜Oi−1(β)∂ζk]−λNO∂[˜Ni(β)˜Oi(β)]∂ζk−λBO∂[˜Bi(β)˜Oi(β)]∂ζk−λO∂˜Oi(β)∂ζk}+δkμ{M2[˜Oi+1(β)−2˜Oi(β)+˜Oi−1(β)]+η+κu(β)−λNO˜Ni(β)˜Oi(β)−λBO˜Bi(β)˜Oi(β)−λO˜Oi(β)}dβ,s∈[μ−1,μ), | (4.11) |
where δkμ denotes the Kronecker delta function. If k>μ, ζk does not affect the ˜Oi(s) during s∈[μ−1,μ), thus we have
∂˜Oi(s)∂ζk=0,s∈[μ−1,μ). | (4.12) |
Then, we differentiate (4.11) corresponding to s and obtain
dds{∂˜Oi(s)∂ζk}=ζμ{M2[∂˜Oi+1(s)∂ζk−2∂˜Oi(s)∂ζk+∂˜Oi−1(s)∂ζk]−λNO∂[˜Ni(s)˜Oi(s)]∂ζk−λBO∂[˜Bi(s)˜Oi(s)]∂ζk−λO∂˜Oi(s)∂ζk}+δkμ{M2[˜Oi+1(s)−2˜Oi(s)+˜Oi−1(s)]+η+κu(s)−λNO˜Ni(s)˜Oi(s)−λBO˜Bi(s)˜Oi(s)−λO˜Oi(s)},s∈[μ−1,μ). | (4.13) |
From (4.10)–(4.13), we can obtain the state variations ∂˜Oi(s)∂ζk for each k=1,2,…,γ, i=1,...,M−1
dds{∂˜Oi(s)∂ζk}=ζμ{M2[∂˜Oi+1(s)∂ζk−2∂˜Oi(s)∂ζk+∂˜Oi−1(s)∂ζk]−λNO∂[˜Ni(s)˜Oi(s)]∂ζk−λBO∂[˜Bi(s)˜Oi(s)]∂ζk−λO∂˜Oi(s)∂ζk}+δkμ{M2[˜Oi+1(s)−2˜Oi(s)+˜Oi−1(s)]+η+κu(s)−λNO˜Ni(s)˜Oi(s)−λBO˜Bi(s)˜Oi(s)−λO˜Oi(s)}, | (4.14) |
where s∈[μ−1,μ), μ=k,k+1,...,γ.
For the initial condition (4.8), we have
∂˜Oi(0)∂ζk=0,k=1,2,…,γ. | (4.15) |
Similarly, we can obtain the state variations ∂˜Ni(s)∂ζk, ∂˜Bi(s)∂ζk and ∂˜Ci(s)∂ζk,k=1,2,…,γ, i=1,...,M−1.
Moreover, for the cost functional (4.9), the gradient formulas corresponding to ζk,k=1,2,…,γ can be obtained using the chain rule of differentiation
∂J(ζ)∂ζk=1MM−1∑i=0∂˜Bi(γ)∂ζk+ω∫kk−1u2(s)ds,k=1,2,…,γ. | (4.16) |
Based on the gradient formulas (4.16), the existing nonlinear programming algorithm, such as Sequential Quadratic Program (SQP) algorithm [33], can be applied to solve the Problem Pγ. The flow chart is shown in Figure 3.
For the computational numerical analysis, the proposed method in Section 4 is implemented in MATLAB software, which uses ODE15s to solve the reduced ODEs (4.7) for the cost functional and gradient formulas and then apply the SQP algorithm to perform the optimization steps. The parameter values for the dimensionless oxygen concentration model and dimensionless neutrophil concentration model are set as: η=0.2284, κ=5.4, λNO=37, λBO=22.7872, λO=2.4667, DN=0.02, κN=10, αBN=14.28, λN=5 and e=30. Meanwhile, the parameter values for dimensionless bacterial concentration model and dimensionless chemoattractant concentration model are set as: DB=0.0001, αB=1.26, KO=0.75, KNR=2, λRB=3.73, λB=5, DC=1.5, αC=20 and λC=0.9, which are consistent with [21]. Moreover, the distribution coefficient ϵ is set as 0.01 and the whole time horizon T is set as 0.432, which corresponds to 24 hours.
The spatial discretization number N is set as 61 and the weight coefficient ω is set as 0.07. Our computational numerical analysis is carried out on a personal computer with the following configuration: Intel(R) Core(TM) i7-6820HQ CPU, 2.70GHz CPU, 16.00GB RAM, 64-bit Windows 10 Operating System.
We divide the whole time horizon into γ=5 time intervals and set corresponding control sequences u(s) as 0, 1, 0, 1, 0. The initial guess for ζk,k=1,...,γ is T/γ, which denotes the equal time intervals. The optimal switching time control sequences under γ=5 are shown in Figure 4a and the dimensionless bacterial concentration at x=0 under γ=5 is shown in Figure 4b. Hyperbaric oxygen therapy is not required due to the high concentration of oxygen at the initial time. Then, it is applied when the oxygen concentration is reduced but the bacterial concentration is still relatively high. Finally, our normal human immune system completely replaces expensive treatments to inhibit or even destroy these bacteria when the bacterial concentration is low. The distribution of the dimensionless oxygen concentration, dimensionless neutrophil concentration, dimensionless bacterial concentration and dimensionless chemoattractant concentration is shown in Figure 5a, 5b, 5c and 5d, respectively. The oxygen concentration (shown in Figure 5a) decreases first, then increases and then decreases due to the optimal switching time control sequences (shown in Figure 4a). The neutrophils (shown in Figure 5b) remain dense near the edge of the chronic wound and are chemically attracted to the center of the chronic wound very slowly. Since the chemoattractant (shown in Figure 5d) does not reach the edge of the chronic wound, neutrophils are lack of movement. Through the regulation of oxygen, the bacterial concentration approaches to 0. Correspondingly, the chemoattractant concentration drops to 0 due to the quick loss of the bacteria.
We extend the number of time intervals into γ=7 and set corresponding control sequences u(s) as 0, 1, 0, 1, 0, 1, 0. The optimal switching time control sequences are shown in Figure 6a and the dimensionless bacterial concentration at x=0 is shown in Figure 6b. The distribution of the dimensionless oxygen concentration and dimensionless bacterial concentration is shown in Figure 7a and 7b, respectively. Since the optimal switching time control sequences (γ=7) are similar to the case of γ=5, the dynamics of oxygen, neutrophils, bacteria and chemoattractants are almost identical to those of γ=5. However, note that increasing γ from 5 to 7 does not lead to any significant change in the inhibition of bacteria. Thus, choosing γ=5 for the time intervals is sufficient.
The results also provide protocols for switching treatment on/off in practice and their meaning in terms of bacterial suppression. From Figures 5a, 5c, 7a and 7b, we can see that when the dimensionless oxygen concentration is less than about 0.75 and the dimensionless bacterial concentration is more than about 0.45, the hyperbaric oxygen therapy is applied effectively. Otherwise, our normal human immune system can inhibit or even destroy these bacteria and the hyperbaric oxygen therapy is not necessary. Note that there are much uncertainty and complex coupling relationship between variables in practice, which will influence the optimal therapeutic effect. Moreover, [31] presents the convergence proof that the optimized control sequences after the time-scaling transformation can approach the theoretic optimal control as γ→+∞. When the number of time intervals is increased to a certain extent, the optimal results are similar and not sensitive to γ. However, we cannot choose γ too large due to consideration of human safety and the limitations of medical conditions. We choose γ=5 (twice a day) and γ=7 (three times a day) in the computational numerical analysis. Our numerical results show that the optimal switching time control sequences are similar when γ is increased from 5 to 7, which means the results are not very sensitive to γ.
Different from traditional empirical strategies, this paper's work can accurately give better protocols for switching treatment on/off at a lower economic cost. Through precise hyperbaric oxygen regulation, bacterial propagation is effectively inhibited, thereby the wound healing is improved. The results of the proposed method can provide some guidance for the medical staff by use of the hyperbaric oxygen therapy for wound healing in practice. Moreover, combined with image recognition technology, our proposed method can be easily extended to the intelligent medical field.
In this paper, we propose the optimal switching time control of the hyperbaric oxygen therapy for bacterial concentration suppression. The bacterial concentration is coupled with the oxygen concentration, neutrophil concentration and chemoattractant concentration governed by PDEs. The method of lines is first used to reduce the PDE optimization problem into an ODE optimization problem. Then, the time-scaling transformation approach is applied and the gradient formulas of the cost functional corresponding to the time intervals are derived based on the sensitivity analysis. Finally, a new effective computational method is proposed and computational numerical analysis shows the effectiveness of the proposed strategy. In the future, we will work on the experiments to further verify the feasibility of the proposed strategy. Moreover, the iterative learning control [34], control parameterization with optimized control values [35,36] and adaptive control [37] for the hyperbaric oxygen therapy can be considered.
This work was partially supported by the National Natural Science Foundation of China 61473253, the Medical Science and Technology Project, Zhejiang Province (2016154240, 2017192644).
All authors declare no conflicts of interest in this paper.
[1] | Howlader N, Noone A, Krapcho M, et al. (2015) SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD. 2015. |
[2] |
Tomasetti C, Li L, Vogelstein B (2017) Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355: 1330-1334. doi: 10.1126/science.aaf9011
![]() |
[3] | Cancer Research UK, Statistics on preventable cancers. 2017. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/risk/preventable-cancers#heading-One |
[4] |
Colditz GA, Hankinson SE (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388-396. doi: 10.1038/nrc1608
![]() |
[5] |
Boeke CE, Eliassen AH, Chen WY, et al. (2014) Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies. Breast Cancer Res Treat 146: 383-392. doi: 10.1007/s10549-014-3005-8
![]() |
[6] |
Farvid MS, Cho E, Chen WY, et al. (2014) Premenopausal dietary fat in relation to pre- and post-menopausal breast cancer. Breast Cancer Res Treat 145: 255-265. doi: 10.1007/s10549-014-2895-9
![]() |
[7] |
Sasaki S, Horacsek M, Kesteloot H (1993) An ecological study of the relationship between dietary fat intake and breast cancer mortality. Prev Med 22: 187-202. doi: 10.1006/pmed.1993.1016
![]() |
[8] |
Chlebowski RT, Blackburn GL, Thomson CA, et al. (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98: 1767-1776. doi: 10.1093/jnci/djj494
![]() |
[9] | Chlebowski RT (2013) Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 22 Suppl 2: S30-37. |
[10] |
Pierce JP, Natarajan L, Caan BJ, et al. (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298: 289-298. doi: 10.1001/jama.298.3.289
![]() |
[11] | Sieri S, Chiodini P, Agnoli C, et al. (2014) Dietary fat intake and development of specific breast cancer subtypes. J Natl Cancer Inst 106. |
[12] |
Cao Y, Hou L, Wang W (2016) Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A meta-analysis of prospective cohort studies. Int J Cancer 138: 1894-1904. doi: 10.1002/ijc.29938
![]() |
[13] |
Bagga D, Anders KH, Wang HJ, et al. (2002) Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer 42: 180-185. doi: 10.1207/S15327914NC422_5
![]() |
[14] |
Murff HJ, Shu XO, Li H, et al. (2011) Dietary polyunsaturated fatty acids and breast cancer risk in Chinese women: a prospective cohort study. Int J Cancer 128: 1434-1441. doi: 10.1002/ijc.25703
![]() |
[15] |
Gago-Dominguez M, Yuan JM, Sun CL, et al. (2003) Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: The Singapore Chinese Health Study. Br J Cancer 89: 1686-1692. doi: 10.1038/sj.bjc.6601340
![]() |
[16] |
Khankari NK, Bradshaw PT, Steck SE, et al. (2015) Dietary intake of fish, polyunsaturated fatty acids, and survival after breast cancer: A population-based follow-up study on Long Island, New York. Cancer 121: 2244-2252. doi: 10.1002/cncr.29329
![]() |
[17] |
Wakai K, Tamakoshi K, Date C, et al. (2005) Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan. Cancer Sci 96: 590-599. doi: 10.1111/j.1349-7006.2005.00084.x
![]() |
[18] |
Kiyabu GY, Inoue M, Saito E, et al. (2015) Fish, n - 3 polyunsaturated fatty acids and n - 6 polyunsaturated fatty acids intake and breast cancer risk: The Japan Public Health Center-based prospective study. Int J Cancer 137: 2915-2926. doi: 10.1002/ijc.29672
![]() |
[19] |
Bagga D, Wang L, Farias-Eisner R, et al. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 100: 1751-1756. doi: 10.1073/pnas.0334211100
![]() |
[20] | Chenais B, Blanckaert V (2012) The janus face of lipids in human breast cancer: how polyunsaturated Fatty acids affect tumor cell hallmarks. Int J Breast Cancer 2012: 712536. |
[21] |
Schwingshackl L, Hoffmann G (2016) Does a Mediterranean-Type Diet Reduce Cancer Risk? Curr Nutr Rep 5: 9-17. doi: 10.1007/s13668-015-0141-7
![]() |
[22] |
van den Brandt PA, Schulpen M (2017) Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis. Int J Cancer 140: 2220-2231. doi: 10.1002/ijc.30654
![]() |
[23] |
Pot GK, Stephen AM, Dahm CC, et al. (2014) Dietary patterns derived with multiple methods from food diaries and breast cancer risk in the UK Dietary Cohort Consortium. Eur J Clin Nutr 68: 1353-1358. doi: 10.1038/ejcn.2014.135
![]() |
[24] |
Toledo E, Salas-Salvado J, Donat-Vargas C, et al. (2015) Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial. JAMA Intern Med 175: 1752-1760. doi: 10.1001/jamainternmed.2015.4838
![]() |
[25] | Farvid MS, Chen WY, Michels KB, et al. (2016) Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study. BMJ 353: i2343. |
[26] |
Liu Y, Colditz GA, Cotterchio M, et al. (2014) Adolescent dietary fiber, vegetable fat, vegetable protein, and nut intakes and breast cancer risk. Breast Cancer Res Treat 145: 461-470. doi: 10.1007/s10549-014-2953-3
![]() |
[27] | Dam MK, Hvidtfeldt UA, Tjonneland A, et al. (2016) Five year change in alcohol intake and risk of breast cancer and coronary heart disease among postmenopausal women: prospective cohort study. BMJ 353: i2314. |
[28] |
Dong JY, Qin LQ (2011) Dietary glycemic index, glycemic load, and risk of breast cancer: meta-analysis of prospective cohort studies. Breast Cancer Res Treat 126: 287-294. doi: 10.1007/s10549-011-1343-3
![]() |
[29] |
Inoue-Choi M, Sinha R, Gierach GL, et al. (2016) Red and processed meat, nitrite, and heme iron intakes and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 138: 1609-1618. doi: 10.1002/ijc.29901
![]() |
[30] |
Touvier M, Fassier P, His M, et al. (2015) Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr 114: 347-357. doi: 10.1017/S000711451500183X
![]() |
[31] |
Tornberg SA, Holm LE, Carstensen JM (1988) Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 27: 31-37. doi: 10.3109/02841868809090315
![]() |
[32] | Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Cancer Res 50: 2341-2346. |
[33] | Furberg AS, Jasienska G, Bjurstam N, et al. (2005) Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 14: 33-40. |
[34] |
Ha M, Sung J, Song YM (2009) Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer Causes Control 20: 1055-1060. doi: 10.1007/s10552-009-9301-7
![]() |
[35] |
Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29: 1592-1598. doi: 10.1200/JCO.2010.31.5200
![]() |
[36] |
Li C, Yang L, Zhang D, et al. (2016) Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer. Nutr Res 36: 627-635. doi: 10.1016/j.nutres.2016.04.009
![]() |
[37] |
McDonnell DP, Park S, Goulet MT, et al. (2014) Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res 74: 4976-4982. doi: 10.1158/0008-5472.CAN-14-1756
![]() |
[38] |
Reeves GK, Pirie K, Beral V, et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335: 1134. doi: 10.1136/bmj.39367.495995.AE
![]() |
[39] |
Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15: 484-498. doi: 10.1038/nrc3967
![]() |
[40] |
Baumgartner KB, Hunt WC, Baumgartner RN, et al. (2004) Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women. Am J Epidemiol 160: 1087-1097. doi: 10.1093/aje/kwh313
![]() |
[41] |
Harris HR, Willett WC, Terry KL, et al. (2011) Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst 103: 273-278. doi: 10.1093/jnci/djq500
![]() |
[42] |
Jiralerspong S, Goodwin PJ (2016) Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. J Clin Oncol 34: 4203-4216. doi: 10.1200/JCO.2016.68.4480
![]() |
[43] |
Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, et al. (2014) Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. Breast Cancer Res Treat 146: 183-188. doi: 10.1007/s10549-014-2977-8
![]() |
[44] |
Printz C (2014) Obesity associated with higher mortality in women with ER-positive breast cancer. Cancer 120: 3267. doi: 10.1002/cncr.29079
![]() |
[45] |
Ottobelli Chielle E, de Souza WM, da Silva TP, et al. (2016) Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem 49: 548-553. doi: 10.1016/j.clinbiochem.2016.01.003
![]() |
[46] |
Bulun SE, Chen D, Moy I, et al. (2012) Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 23: 83-89. doi: 10.1016/j.tem.2011.10.003
![]() |
[47] |
Creighton CJ, Sada YH, Zhang Y, et al. (2012) A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat 132: 993-1000. doi: 10.1007/s10549-011-1595-y
![]() |
[48] |
Perks CM, Holly JM (2011) Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin North Am 40: 485-507, vii. doi: 10.1016/j.ecl.2011.05.010
![]() |
[49] |
Vadgama JV, Wu Y, Datta G, et al. (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330-340. doi: 10.1159/000012052
![]() |
[50] |
Kaaks R, Lundin E, Rinaldi S, et al. (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13: 307-316. doi: 10.1023/A:1015270324325
![]() |
[51] |
Sugumar A, Liu YC, Xia Q, et al. (2004) Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111: 293-297. doi: 10.1002/ijc.20253
![]() |
[52] |
Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13: 273-278. doi: 10.1677/erc.1.01219
![]() |
[53] |
Endogenous H, Breast Cancer Collaborative G, Key TJ, et al. (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11: 530-542. doi: 10.1016/S1470-2045(10)70095-4
![]() |
[54] |
Rinaldi S, Peeters PH, Berrino F, et al. (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593-605. doi: 10.1677/erc.1.01150
![]() |
[55] |
Allen NE, Roddam AW, Allen DS, et al. (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92: 1283-1287. doi: 10.1038/sj.bjc.6602471
![]() |
[56] | Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, et al. (2005) Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 14: 48-52. |
[57] |
Schairer C, Hill D, Sturgeon SR, et al. (2004) Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-779. doi: 10.1002/ijc.11624
![]() |
[58] |
Signori C, DuBrock C, Richie JP, et al. (2012) Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr 66: 878-884. doi: 10.1038/ejcn.2012.60
![]() |
[59] |
Kabat GC, Kim M, Caan BJ, et al. (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125: 2704-2710. doi: 10.1002/ijc.24609
![]() |
[60] | Goodwin PJ, Ennis M, Pritchard KI, et al. (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30: 164-171. |
[61] | Sun W, Lu J, Wu S, et al. (2016) Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res 6: 2334-2344. |
[62] |
Lee JO, Kim N, Lee HJ, et al. (2016) Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep 6: 18923. doi: 10.1038/srep18923
![]() |
[63] |
Sun CA, Wu MH, Chu CH, et al. (2010) Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat 123: 869-876. doi: 10.1007/s10549-010-0792-4
![]() |
[64] | Dalamaga M, Sotiropoulos G, Karmaniolas K, et al. (2013) Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem 46: 584-590. |
[65] |
Georgiou GP, Provatopoulou X, Kalogera E, et al. (2016) Serum resistin is inversely related to breast cancer risk in premenopausal women. Breast 29: 163-169. doi: 10.1016/j.breast.2016.07.025
![]() |
[66] |
Rahbar AR, Nabipour I (2014) The relationship between dietary lipids and serum visfatin and adiponectin levels in postmenopausal women. Endocr Metab Immune Disord Drug Targets 14: 84-92. doi: 10.2174/1871530314666140527143009
![]() |
[67] |
Dalamaga M, Karmaniolas K, Papadavid E, et al. (2011) Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 18: 1198-1204. doi: 10.1097/gme.0b013e31821e21f5
![]() |
[68] |
Lee YC, Yang YH, Su JH, et al. (2011) High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol Biomarkers Prev 20: 1892-1901. doi: 10.1158/1055-9965.EPI-11-0399
![]() |
[69] |
Kim SR, Park HJ, Bae YH, et al. (2012) Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology 153: 554-563. doi: 10.1210/en.2011-1413
![]() |
[70] |
Li C, Li J, Chen Y, et al. (2016) Effect of curcumin on visfatin and zinc-alpha2-glycoprotein in a rat model of non-alcoholic fatty liver disease. Acta Cir Bras 31: 706-713. doi: 10.1590/s0102-865020160110000001
![]() |
[71] |
Gao Y, Wang C, Pan T, et al. (2014) Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. Arq Bras Endocrinol Metabol 58: 42-47. doi: 10.1590/0004-2730000002840
![]() |
[72] |
Maffei M, Halaas J, Ravussin E, et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161. doi: 10.1038/nm1195-1155
![]() |
[73] |
Thompson HJ, Sedlacek SM, Wolfe P, et al. (2015) Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors. Nutrients 7: 5156-5176. doi: 10.3390/nu7075156
![]() |
[74] |
Alshaker H, Wang Q, Frampton AE, et al. (2015) Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Res Treat 149: 59-67. doi: 10.1007/s10549-014-3228-8
![]() |
[75] |
Park HS, Park JY, Yu R (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 69: 29-35. doi: 10.1016/j.diabres.2004.11.007
![]() |
[76] |
Bowers LW, Brenner AJ, Hursting SD, et al. (2015) Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production. Breast Cancer Res Treat 149: 49-57. doi: 10.1007/s10549-014-3223-0
![]() |
[77] |
Imayama I, Ulrich CM, Alfano CM, et al. (2012) Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 72: 2314-2326. doi: 10.1158/0008-5472.CAN-11-3092
![]() |
[78] | Gao D, Rahbar R, Fish EN (2016) CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol 6. |
[79] |
Svensson S, Abrahamsson A, Rodriguez GV, et al. (2015) CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. Clin Cancer Res 21: 3794-3805. doi: 10.1158/1078-0432.CCR-15-0204
![]() |
[80] |
Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al. (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12: 4474-4480. doi: 10.1158/1078-0432.CCR-06-0074
![]() |
[81] | D'Esposito V, Liguoro D, Ambrosio MR, et al. (2016) Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. Oncotarget 7: 24495-24509. |
[82] |
Li BH, He FP, Yang X, et al. (2017) Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res 180: 103-117 e104. doi: 10.1016/j.trsl.2016.08.006
![]() |
[83] |
Bell LN, Ward JL, Degawa-Yamauchi M, et al. (2006) Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab 291: E843-848. doi: 10.1152/ajpendo.00174.2006
![]() |
[84] |
Sundaram S, Freemerman AJ, Johnson AR, et al. (2013) Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat 142: 489-503. doi: 10.1007/s10549-013-2741-5
![]() |
[85] | Ristimaki A, Sivula A, Lundin J, et al. (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635. |
[86] |
Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192. doi: 10.1054/bjoc.2000.1709
![]() |
[87] | Brown KA, Simpson ER (2012) Obesity and breast cancer: mechanisms and therapeutic implications. Front Biosci (Elite Ed) 4: 2515-2524. |
[88] | Davies NJ, Batehup L, Thomas R (2011) The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 105 Suppl 1: S52-73. |
[89] |
Cuzick J, Warwick J, Pinney E, et al. (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103: 744-752. doi: 10.1093/jnci/djr079
![]() |
[90] |
Kaaks R, Bellati C, Venturelli E, et al. (2003) Effects of dietary intervention on IGF-I and IGF-binding proteins, and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomised Trial. Eur J Clin Nutr 57: 1079-1088. doi: 10.1038/sj.ejcn.1601647
![]() |
[91] | Wei M, Brandhorst S, Shelehchi M, et al. (2017) Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med 9. |
[92] |
Sandhu N, Schetter SE, Liao J, et al. (2016) Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial. Cancer Prev Res (Phila) 9: 275-282. doi: 10.1158/1940-6207.CAPR-15-0235
![]() |
[93] |
Sanderson M, Peltz G, Perez A, et al. (2010) Diabetes, physical activity and breast cancer among Hispanic women. Cancer Epidemiol 34: 556-561. doi: 10.1016/j.canep.2010.06.001
![]() |
[94] |
Irwin ML, Varma K, Alvarez-Reeves M, et al. (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev 18: 306-313. doi: 10.1158/1055-9965.EPI-08-0531
![]() |
1. | Siyi Chen, Jing Lu, Tianhui You, Duanping Sun, Metal-organic frameworks for improving wound healing, 2021, 439, 00108545, 213929, 10.1016/j.ccr.2021.213929 | |
2. | Mohammad A Alghamdi, Metal-Organic Frameworks for Diabetic Wound Healing, 2023, 2168-8184, 10.7759/cureus.39557 | |
3. | Fereshte Hassanzadeh Afruzi, Majid Abdouss, Ehsan Nazarzadeh Zare, Erfan Rezvani Ghomi, Shima Mahmoudi, Rasoul Esmaeely Neisiany, Metal-organic framework-hydrogel composites as emerging platforms for enhanced wound healing applications: Material design, therapeutic strategies, and future prospects, 2025, 524, 00108545, 216330, 10.1016/j.ccr.2024.216330 |